Eyepoint Pharma (EYPT)
NASDAQ:EYPT
Want to see EYPT full AI Analyst Report?
EYPT Stock Chart & Stats
$14.93
$0.01(0.11%)
At close: 4:00 PM EST
$14.93
$0.01(0.11%)
Day’s Range― - ―
52-Week Range$7.11 - $19.11
Previous CloseN/A
Volume354.62K
Average Volume (3M)899.10K
Market Cap
$1.13B
Enterprise Value$1.07B
Total Cash (Recent Filing)$222.54M
Total Debt (Recent Filing)$20.23M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Aug 05, 2026EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.50
Shares Outstanding83,841,300
10 Day Avg. Volume912,752
30 Day Avg. Volume899,098
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)4.37
Price to Sales (P/S)42.66
P/FCF Ratio-5.50
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue141.09
Enterprise Value/Gross Profit184.41
Enterprise Value/Ebitda-3.86
Forecast
1Y Price Target
$36.40Price Target Upside143.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.5
Revenue Forecast (FY)$1.69M
Bulls Say, Bears Say
Bulls Say
Differentiated Multi‑mechanism MOA And Phase II DurabilityDURAVYU’s multi-mechanism profile (VEGF, PDGF, JAK1/IL-6) and durable Phase II responses across >190 patients imply clinical differentiation versus pure anti‑VEGF biologics. That structural differentiation can support sustainable market share and pricing if pivotal data and approvals follow.
Favorable Safety Oversight & Uninterrupted Pivotal TrialsThree consecutive positive DSMC reviews materially reduce near-term safety and protocol risk, preserving trial timelines and data integrity. Lower regulatory/safety uncertainty improves the odds of clear top-line results and supports a credible path toward filing and commercialization.
Manufacturing Readiness And Funded Runway Into Q4 2027Having a commercial-grade manufacturing site online plus a cash runway through Q4 2027 reduces execution risk for CMC/NDA activities and initial launch supply. This structural preparedness supports faster commercialization and less dependency on immediate external manufacturing partnerships.
Bears Say
Severe Cash Burn And Negative Operating Cash FlowSustained negative operating and free cash flow at this scale materially increases financing risk and the likelihood of dilution or costly external funding. Persistent cash burn also limits flexibility for commercial investment and raises execution risk if pivotal outcomes are delayed.
Sharp Revenue Collapse And Limited Current Commercial SalesA dramatic revenue decline shrinks the company’s ability to absorb fixed R&D and commercial scaling costs. Until new approvals or launches generate sustainable sales, the business remains highly dependent on trial success and external financing rather than organic product cash flow.
Rising Operating Expenses And Widening Net LossesEscalating trial and commercial scale-up costs are expanding operating losses, accelerating capital depletion. If expected product milestones slip or require additional studies, higher ongoing expenses make capital raises likelier and can dilute shareholders and constrain long-term strategic optionality.
EyePoint Pharmaceuticals News
EYPT FAQ
What was Eyepoint Pharma’s price range in the past 12 months?
Eyepoint Pharma lowest stock price was $7.11 and its highest was $19.11 in the past 12 months.
What is Eyepoint Pharma’s market cap?
Eyepoint Pharma’s market cap is $1.13B.
When is Eyepoint Pharma’s upcoming earnings report date?
Eyepoint Pharma’s upcoming earnings report date is Aug 05, 2026 which is in 66 days.
How were Eyepoint Pharma’s earnings last quarter?
Eyepoint Pharma released its earnings results on May 06, 2026. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.805 by -$0.185.
Is Eyepoint Pharma overvalued?
According to Wall Street analysts Eyepoint Pharma’s price is currently Undervalued.
Does Eyepoint Pharma pay dividends?
Eyepoint Pharma does not currently pay dividends.
What is Eyepoint Pharma’s EPS estimate?
Eyepoint Pharma’s EPS estimate is -0.94.
How many shares outstanding does Eyepoint Pharma have?
Eyepoint Pharma has 83,841,300 shares outstanding.
What happened to Eyepoint Pharma’s price movement after its last earnings report?
Eyepoint Pharma reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.805. Following the earnings report the stock price went down -2.909%.
Which hedge fund is a major shareholder of Eyepoint Pharma?
Currently, no hedge funds are holding shares in EYPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.40 (143.80% Upside)
$36.40 (143.80% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $60.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
88.34%
12-Months-Change
Fundamentals
Return on Equity
-110.54%
Trailing 12-Months
Asset Growth
-20.51%
Trailing 12-Months
Company Description
Eyepoint Pharma
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
EYPT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed robust clinical and operational momentum: imminent Phase III wet AMD readouts, strong DME enrollment, favorable Phase II data and a differentiated MOA, supported by manufacturing and commercial preparations. Offsetting this are steep year-over-year revenue decline (driven by prior deferred revenue recognition), rising operating expenses, a larger quarterly net loss and a notable quarter-over-quarter cash reduction. Management projects cash runway into Q4 2027, and masked safety data and DSMC recommendations to date are favorable. Overall, the clinical and strategic positives tied to near-term pivotal catalysts moderately outweigh the financial headwinds.View all EYPT earnings summariesEYPT Stock 12 Month Forecast
Average Price Target
$36.40
▲(143.80% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
10.76% Insiders
19.58% Mutual Funds
50.08% Other Institutional Investors
7.87% Public Companies and
Individual Investors